News 09.09.2021 Schlieren (Zurich), Switzerland, 9 September, 2021 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Easypack Putty, a soft and moldable formulation ideal for packing into...
News 11.08.2021 Schlieren (Zurich), Switzerland, August 11, 2021 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half of 2021. Kuros accelerated its product sales by 279% compared to the same period last year. In addition, it received CHF 5.5 million in milestone...
News 10.08.2021 ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today the receipt of notification from its partner, AbbVie Inc., regarding...
News 15.07.2021 Schlieren (Zurich), Switzerland, 15 July, 2021 – Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone...
News 08.07.2021 Schlieren (Zurich), 8 July 2021 - LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Germany of a 4-valent candidate vaccine to help prevent Klebsiella infections. LimmaTech is developing the asset in collaboration with GSK. Klebsiella is a bacterium threatening humans in many different settings, including...